Balt announced that it received CE Mark approval for its Silk Vista flow diverting stent for treating patients with unruptured intracranial aneurysms.
Montmorency, France.-based Balt designed its Silk Vista device for predictable and accurate deployment and high visibility under angiography, adding to its already-CE-Marked Silk Vista baby flow diverter, which has been approved in Europe since 2018.
University of Toronto professor and endovascular neurosurgeon Dr. Vitor Mendes Pereira, who performed the first-in-man case of Silk Vista in Toronto last month, said in a news release that Silk Vista offers improved visibility for treating aneurysms arising off of neurovascular vessels 3.5 mm and larger.
“Balt has provided physicians for decades with unique, life-saving products to treat patients with neurovascular conditions and has been a pioneer in flow diversion technologies,” Balt CEO Pascal Girin said in the release. “The Silk Vista is an exceptional flow diverter, and we believe its elegant design and ease-of-use will lead to its rapid clinical adoption in treating aneurysms.”
